Cite
Landiolol, an ultra-short acting beta-1 blocker, for preventing postoperative lung cancer recurrence: study protocol for a phase III, multicenter randomized trial with two parallel groups of patients
MLA
Haruko Yamamoto, et al. “Landiolol, an Ultra-Short Acting Beta-1 Blocker, for Preventing Postoperative Lung Cancer Recurrence: Study Protocol for a Phase III, Multicenter Randomized Trial with Two Parallel Groups of Patients.” Trials, vol. 20, no. 1, Dec. 2019, pp. 1–6. EBSCOhost, https://doi.org/10.1186/s13063-019-3904-4.
APA
Haruko Yamamoto, Toshimitsu Hamasaki, Kaori Onda, Takashi Nojiri, Masato Aragaki, Nao Horie, Norihiro Sato, & Yasuhiro Hida. (2019). Landiolol, an ultra-short acting beta-1 blocker, for preventing postoperative lung cancer recurrence: study protocol for a phase III, multicenter randomized trial with two parallel groups of patients. Trials, 20(1), 1–6. https://doi.org/10.1186/s13063-019-3904-4
Chicago
Haruko Yamamoto, Toshimitsu Hamasaki, Kaori Onda, Takashi Nojiri, Masato Aragaki, Nao Horie, Norihiro Sato, and Yasuhiro Hida. 2019. “Landiolol, an Ultra-Short Acting Beta-1 Blocker, for Preventing Postoperative Lung Cancer Recurrence: Study Protocol for a Phase III, Multicenter Randomized Trial with Two Parallel Groups of Patients.” Trials 20 (1): 1–6. doi:10.1186/s13063-019-3904-4.